DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

2040
INDEX
K
Kallidin, 926–932, 927f
[des-Arg 10 ]-, structure of, 928t
des-Arg 10 -[Leu 9 ]-, structure of, 928t
history of, 926
metabolism of, 927
structure of, 928t
Kallidinogen, history of, 926
Kallikrein, 926
functions of, 929
inhibitors of, 931–932
pharmacology of, 930–932
plasma, 927f, 929
tissue, 927f, 929
Kallikrein-kininogen-kinin system,
927–930
Kallikrein-kinin system, 927f
KALTERA (lopinavir), 1626t
Kanamycin, 1517–1518
Kaposi sarcoma, drugs for,
1668t–1670t, 1823, 1824
Kaposi’s sarcoma, drugs for,
1668t–1670t
Kawasaki disease, 976
KEFLEX (cephalexin), 1494t, 1496t
KEFLIN (cephalothin), 1494t, 1496t
KEFUROX (cefuroxime), 1494t, 1496t
KEFZOL (cefazolin), 1494t, 1496t
Kelp, 1153t
KENALOG (triamcinolone acetonide),
1225t, 1808t
Keratin, 1803, 1805f
Keratitis
fungal, 1783
muscarinic antagonists and, 233
parasitic, 1783
yeast, 1784t
Keratoconjunctivitis
bacterial, treatment of, 1781t
viral, 1783t
Keratolytic agents, 1829
Ketamine
as anesthetic, 542–543
formulations of, 538t
pharmacology of, 538t, 544t
Ketanserin, 310, 350
Ketoacidosis, insulin treatment of,
1255
Ketoconazole, 1235, 1576, 1588, 1817
drug interactions with, 129
effects on steroidogenesis,
1766–1767, 1766f
indications for, 1816t
mechanism of action of, 1841
therapeutic uses of, 1841
Ketoconazole, ABC transporters and,
105t
Ketolides
absorption of, 1531
antimicrobial activity of, 1529–1530
distribution of, 1531
drug interactions with, 1534
elimination of, 1531–1532
resistance to, 1530–1531
therapeutic uses of, 1532–1533
untorward effects of, 1533–1534
Ketoprofen, 989
compared to aspirin, 969t
COX isoform selectivity, 962f
dosage and administration of, 969t
pharmacokinetics of, 969t
pharmacology of, 962f
plasma pharmacokinetics of, 962f
structure of, 988f
therapeutic uses of, 969t
Ketorolac
adverse effects and side effects of,
986
compared to aspirin, 967t
COX isoform selectivity, 962f
dosage and administration of, 967t
pharmacokinetics of, 967t, 1855t
pharmacology of, 962f
structure of, 986
therapeutic uses of, 967t, 986
Ketotifen fumarate, 922
for ophthalmic use, 1789
Kidd antigen blood group, 102t
Kidney(s)
ABC transporters in, 103–104,
105t–106t
alpha adrenergic receptors in, 203t
anatomy and physiology, 671–677,
672f
in autonomic nervous system, 179t
beta adrenergic receptors in, 204t
and blood pressure regulation, 698f
clearance by, 30
dopamine and, 355
eicosanoids and, 947–948, 950
in excretion, 26
halothane and, 547
handling of specific anions and
cations, 676–677
isoflurane and, 548
kinins and, 931
parathyroid hormone and, 1279
platelet-activating factor and, 955
transporters in, 111–115
vectorial transport in, 96f
Kinetics, of transport, 95–96
Kinin agonists, structure of, 928t
Kinin antagonists, structure of, 928t
Kininase I, 926
Kininase II, 926, 929
Kininogens, 927
high-molecular-weight, 852, 927,
927f, 929
low-molecular-weight, 927, 927f, 929
synthesis of, 929
Kinin receptor(s), 929–930
antagonists, 932
Kinins, 926–932
cardiovascular effects of, 931
clinical summary, 932–933
functions of, 930–932
histamine and, 914
history of, 926
metabolism of, 929
pharmacology of, 930–932
renal effects of, 931
and respiratory function, 931
synthesis of, 927–929
therapeutic uses of, potential, 931
KLARON (sulfacetamide), 1817
Klotho, 1285
KLOUT SHAMPOO (acetic acid +
isopropanol), 1818
KONAKION (phytonadione), 873
KUDROX, 1316t
KW-3902, therapeutic uses of, for
heart failure, 793
KYNAPID (vernakalant), 845
L
Labeling
in drug approval process, 9
indications in, 9
Labetalol, 328–329
as antihypertensive agent, 774t,
780–781
strucutre of, 311f
therapeutic uses of, for
hypertension, in pregnancy,
1847
Labor. See also Preterm labor
dysfunctional
augmentation of, 1850
oxytocin for, 1850
eicosanoids and, 948
induction of, 1849–1850
Lacosamide, 602
Lacrimal system, 1773
cervimeline and, 224
pilocarpine and, 224